“…removal of cytokines. [12][13] Third, since no significant associations were found when appraising death risk according to country, center, or institutional volume, it is reasonable to speculate that ECMO technology may be safely applied in all ECMO centers by experienced users applying state of the art techniques and ancillary management and not only in high volume centers, especially when ECMO therapy is implemented with careful optimization of anticoagulation, thus minimizing inflammatory and thrombotic complications leading to microvascular COVID-19 lung vessels obstructive thromboinflammatory syndrome (MicroCLOTS). 14 Taken together these findings highlight the current role of ECMO in COVID-19, reassuring on its short-term favorable results even in low-volume centers and in both genders, which may open new perspectives and induce an improvement of World Health Organization interim guidelines.…”